Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 48,493 shares, an increase of 52.6% from the July 15th total of 31,784 shares. Based on an average trading volume of 11,695 shares, the short-interest ratio is presently 4.1 days.
Relief Therapeutics Stock Up 13.9%
RLFTF opened at $0.32 on Tuesday. Relief Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $4.88. The business has a 50-day moving average of $0.27 and a 200-day moving average of $0.56.
About Relief Therapeutics
Relief Therapeutics AG is a clinical?stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF?100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
See Also
- Five stocks we like better than Relief Therapeutics
- Orbiting Wealth: Institutions Load Up SpaceX
- Uncle Sam’s Chip Trick: How the Government Built a Silicon Moat
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
